Showing 2501-2510 of 2530 results for "".
- Telescope Implant for End-State Macular Degeneration Now on the Federal Supply Schedule and Available at VA Hospitalshttps://modernod.com/news/telescope-implant-for-end-state-macular-degeneration-now-on-the-federal-supply-schedule-and-available-at-va-hospitals/2480149/VisionCare announced that MellingMedical will distribute the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) to Department of Veteran’s Affairs hospitals, military hospitals, and other federal government healthcare facilities in the United States. MellingMedical provides medical su
- President Trump Outlines Plan to Lower Drug Costshttps://modernod.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/President Donald Trump on Friday unveiled plans to increase competition in the prescription medicine market and lower patients’ out-of-pocket costs in an effort to tackle high drug prices in the US. Under the plan, dubbed American Patients First, rules preventing government programmes from
- Moorfields Eye Hospital Dubai in Collaboration with Moorfields Eye Hospital Abu Dhabi Develop Procedure to Diagnose Retinal Problems in Childrenhttps://modernod.com/news/moorfields-eye-hospital-dubai-in-collaboration-with-moorfields-eye-hospital-abu-dhabi-develop-procedure-to-diagnose-retinal-problems-in-children/2480152/A medical study on diagnosing children undertaken in the United Arab Emirates by a team of four consultants at Moorfields Eye Hospital Dubai and Moorfields Eye Hospital Abu Dhabi has achieved the distinction of becoming the first medical study undertaken entirely in the UA
- Genome Surgery for Eye Disease Moves Closer to Realityhttps://modernod.com/news/genome-surgery-for-eye-disease-moves-closer-to-reality/2480154/Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. This is the first time researchers have successfully app
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- Free Cataract Removal Surgeries for Those in Needhttps://modernod.com/news/free-cataract-removal-surgeries-for-those-in-need/2480160/The Hawaiian Eye Foundation (HEF) performs free sight-restoring cataract surgeries for those that are uninsured and underinsured in Hawaii. With the incredible support of the Atherton Family Foundation, the 2nd Annual
- LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drughttps://modernod.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National I
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held